Arterial stiffness, hypertension, and rational use of nebivolol

References

• BoutouyriePLaurentSBrietMImportance of arterial stiffness as cardiovascular risk factor for future development of new type of drugsFundam Clin Pharmacol20082224124618485143
   PubMed Web of Science ®Google Scholar
• MahmudAFeelyJSpurious systolic hypertension of youth: fit young men with elastic arteriesAm J Hypertens200316322923212620702
   PubMed Web of Science ®Google Scholar
• LaurentSCockcroftJVan BortelLthe European Network for Non-invasive Investigation of Large ArteriesExpert consensus document on arterial stiffness: methodological issues and clinical applicationsEur Heart J2006272588260517000623
   PubMed Web of Science ®Google Scholar
• Agabiti-RoseiEManciaGO’RourkeMFCentral blood pressure measurements and antihypertensive therapy: a consensus documentHypertension20075015416017562972
   PubMed Web of Science ®Google Scholar
• McEnieryCMYasminHallIRQasemAWilkinsonIBCockcroftJRACCT InvestigatorsNormal vascular aging: differential effects on wave reflection and aortic pulse wave velocity: the Anglo-Cardiff Collaborative Trial (ACCT)Am Coll Cardiol200546917531760
   PubMed Web of Science ®Google Scholar
• MahmudAFeelyJArterial stiffness is related to systemic inflammation in essential hypertensionHypertension2005461118112216216991
   PubMed Web of Science ®Google Scholar
• AmarJRuidavetsJBPeyrieuxJCC-reactive protein elevation predicts pulse pressure reduction in hypertensive subjectsHypertension20054615115515956115
   PubMed Web of Science ®Google Scholar
• LondonGMAsmarRGO’RourkeMFSafarMEReason Project InvestigatorsMechanism(s) of selective systolic blood pressure reduction after a low-dose combination of perindopril/indapamide in hypertensive subjects: comparison with atenololJ Am Coll Cardiol200443929914715189
   PubMed Web of Science ®Google Scholar
• HirataKVlachopoulosCAdjiAO’RourkeMFBenefits from angiotensin-converting enzyme inhibitor ‘beyond blood pressure lowering’: beyond blood pressure or beyond the brachial arteryJ Hypertens20052355155615716696
   PubMed Web of Science ®Google Scholar
• WilliamsBLacyPSThomSMCAFE InvestigatorsAnglo-Scandinavian Cardiac Outcomes Trial InvestigatorsCAFE Steering Committee and Writing CommitteeDifferential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFÉ) studyCirculation20061131213122516476843
   PubMed Web of Science ®Google Scholar
• De LucaNAsmarRLondonGMO’RourkeMFSafarMEREASON Project InvestigatorsSelective reduction of cardiac mass and central blood pressure on low-dose combination perindopril/indapamide in hypertensive subjectsJ Hypertens2004221623163015257187
   PubMed Web of Science ®Google Scholar
• SafarMERizzoniDBlacherJMuiesanMLAgabiti-RoseiEMacro and microvasculature in hypertension: therapeutic aspectsJ Hum Hypertens200822959059518509346
   PubMed Web of Science ®Google Scholar
• WilkinsonIBMacCallumHFlintLCockcroftJRNewbyDEWebbDJThe influence of heart rate on augmentation index and central arterial pressure in humansJ Physiol (Lond)200052526327010811742
   PubMedGoogle Scholar
• TingCTYangTMChenJWChangMSYinFCArterial hemodynamics in human hypertension. Effects of angiotensin converting enzyme inhibitionHypertension1993228398468244515
   PubMed Web of Science ®Google Scholar
• ChenCHTingCTLinSJHsuFCPSiuCOChouPDifferent effects of fosinopril and atenolol on wave reflections in hypertensionHypertension199525103410417737712
   PubMed Web of Science ®Google Scholar
• TingCTChenC-HChangM-SYinFCPShort- and long-term effects of antihypertensive drugs on arterial reflections compliance and impedanceHypertension1995265245307649593
   PubMed Web of Science ®Google Scholar
• MorganTLauriJBertramDAndersonAEffect of different antihypertensive drug classes on central aortic pressureAm J Hypertens20047211812314751652
   PubMedGoogle Scholar
• Agabiti RoseiERizzoniDMetabolic profile of nebivolol, a beta-adrenoceptor antagonist with unique characteristicsDrugs2007671097110717521213
   PubMed Web of Science ®Google Scholar
• BroedersMAWDoevendansPABekkersBCAMNebivolol: a third-generation β-blocker that augments vascular nitric oxide release. Endothelial β2-adrenergic receptor-mediated nitric oxide productionCirculation200010267768210931809
   PubMed Web of Science ®Google Scholar
• CockcroftJRChowienczykPJBrettSENebivolol vasodilates human forearm vasculature: evidence for an L-arginine/NO-dependent mechanismJ Pharmacol Exp Ther1995274106710717562470
   PubMed Web of Science ®Google Scholar
• TzemosNLimPOMacDonaldTMNebivolol reverses endothelial dysfunction in essential hypertension. A randomised, double blind crossover studyCirculation200110451151411479245
   PubMed Web of Science ®Google Scholar
• GuptaSWrightHMNebivolol: a highly selective beta1-adrenergic receptor blocker that causes vasodilation by increasing nitric oxideCardiovasc Ther200826318920218786089
   PubMed Web of Science ®Google Scholar
• AndreDEArnetUYangZLuscherTFNebivolol inhibits human aortic smooth muscle cell growth: effects on cell cycle regulatory proteinsJ Cardiovasc Pharmacol20003584584810836716
   PubMed Web of Science ®Google Scholar
• Fratta PasiniAGarbinUNavaMCNebivolol decreases oxidative stress in essential hypertensive patients and increases nitric oxide by reducing its oxidative inactivationJ Hypertens20052358959615716701
   PubMed Web of Science ®Google Scholar
• OelzeMDaiberABrandesRPNebivolol inhibits superoxide formation by NADPH oxidase and endothelial dysfunction in angiotensin II-treated ratsHypertension200648467768416940222
   PubMed Web of Science ®Google Scholar
• DessyCSaliezJGhisdalPEndothelial beta3-adrenoreceptors mediate nitric oxide-dependent vasorelaxation of coronary microvessels in response to the third-generation beta-blocker nebivololCirculation200511281198120516116070
   PubMed Web of Science ®Google Scholar
• PasiniAFGarbinUStranieriCNebivolol treatment reduces serum levels of asymmetric dimethylarginine and improves endothelial dysfunction in essential hypertensive patientsAm J Hypertens200821111251125718772860
   PubMed Web of Science ®Google Scholar
• CominaciniLFratta PasiniAGarbinUNebivolol and its 4-keto derivative increase nitric oxide in endothelial cells by reducing its oxidative inactivationJ Am Coll Cardiol2003421838184414642697
   PubMed Web of Science ®Google Scholar
• TaddeiSVirdisAGhiadoniLEffect of calcium antagonist or beta blockade treatment on nitric oxide-dependent vasodilation and oxidative stress in essential hypertensive patientsJ Hypertens2001191379138611518845
   PubMed Web of Science ®Google Scholar
• PoirierLClerouxJNadeauALacourciereYEffects of nebivolol and atenolol on insulin sensitivity and haemodynamics in hypertensive patientsJ Hypertens2001191429143511518851
   PubMed Web of Science ®Google Scholar
• FogariRZoppiALazzariPComparative effects of nebivolol and atenolol on blood pressure and insulin sensitivity in hypertensive subjects with type II diabetesJ Hum Hypertens1997117537579416986
   PubMed Web of Science ®Google Scholar
• CockcroftJA review of the safety and efficacy of nebivolol in the mildly hypertensive patientVasc Health Risk Manag2007390991718200810
   PubMedGoogle Scholar
• LiebWLarsonMGBenjaminEJMultimarker approach to evaluate correlates of vascular stiffness: the Framingham Heart StudyCirculation20091191374319103986
   PubMed Web of Science ®Google Scholar
• GrayCLNdefoUANebivolol: a new antihypertensive agentAm J Health Syst Pharm2008651125123318541682
   PubMed Web of Science ®Google Scholar
• MahmudAFeelyJBeta-blockers reduce aortic stiffness in hypertension but nebivolol, not atenolol, reduces wave reflectionAm J Hypertens20082166366718437130
   PubMed Web of Science ®Google Scholar
• DhakamZYasminMcEnieryCMBurtonTBrownMJWilkinsonIBA comparison of atenolol and nebivolol in isolated systolic hypertensionJ Hypertens20082635123618192850
   PubMed Web of Science ®Google Scholar
• KaiserTHeiseTNosekLEckersUSawickiPTInfluence of nebivolol and enalapril on metabolic parameters and arterial stiffness in hypertensive type 2 diabetic patientsJ Hypertens2006241397140316794490
   PubMed Web of Science ®Google Scholar
• McEnieryCMSchmittMQasemANebivolol increases arterial distensibility in vivoHypertension20044430531015262912
   PubMed Web of Science ®Google Scholar
• ArosioEDe MarchiSPriorMZannoniMLechiAEffects of nebivolol and atenolol on small arteries and microcirculatory endothelium-dependent dilation in hypertensive patients undergoing isometric stressJ Hypertens20022091793179712195121
   PubMed Web of Science ®Google Scholar
• Van BortelLFocus on small artery stiffnessJ Hypertens2002201707170912195105
   PubMed Web of Science ®Google Scholar
• PedersenMECockcroftJRThe latest generation of beta-blockers: new pharmacologic propertiesCurr Hypertens Rep2006827928616884657
   PubMed Web of Science ®Google Scholar
• CockcroftJRExploring vascular benefits of endothelium-derived nitric oxideAm J Hypertens200518(12 Pt 2)177S183S16373196
   PubMed Web of Science ®Google Scholar
• CockcroftJNebivolol: a reviewExpert Opin Pharmacother2004589389915102571
   PubMed Web of Science ®Google Scholar
• ThuillezCRichardVTargeting endothelial dysfunction in hypertensive subjectsJ Hum Hypertens200519Suppl 1S21S2516075029
   PubMedGoogle Scholar
• ZanchettiAClinical pharmacodynamics of nebivolol: new evidence of nitric oxide-mediated vasodilating activity and peculiar haemodynamic properties in hypertensive patientsBlood Press20041Suppl1732
   Google Scholar